GeneDx Holdings/$WGS
1D1W1MYTD1Y5YMAX
About GeneDx Holdings
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
- Ticker
- $WGS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,300
- Headquarters
- Stamford, United States
- Website
- www.genedx.com
GeneDx Holdings Metrics
BasicAdvanced
$2.6B
-
-$3.64
1.97
-
Price and volume
Market cap
$2.6B
Beta
1.97
52-week high
$170.87
52-week low
$32.21
Average daily volume
764K
Financial strength
Current ratio
3.301
Quick ratio
2.896
Long term debt to equity
66.208
Total debt to equity
68.545
Interest coverage (TTM)
-20.00%
Profitability
EBITDA (TTM)
-33.695
Gross margin (TTM)
69.38%
Net profit margin (TTM)
-23.40%
Operating margin (TTM)
-13.13%
Effective tax rate (TTM)
-0.06%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-7.89%
Return on equity (TTM)
-40.80%
Valuation
Price to revenue (TTM)
5.599
Price to book
10.62
Price to tangible book (TTM)
25.63
Price to free cash flow (TTM)
-33.565
Free cash flow yield (TTM)
-2.98%
Free cash flow per share (TTM)
-2.594
Growth
Revenue change (TTM)
25.42%
Earnings per share change (TTM)
-7,610.63%
3-year revenue growth (CAGR)
24.33%
3-year earnings per share growth (CAGR)
-49.77%
GeneDx Holdings News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.